ArticleMedicine2026
Gd-EOB-DTPA MRI radiomics-clinical nomogram for preoperatively predicting dual-positive Ki-67/MVI status in hepatocellular carcinoma: A retrospective study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The Ki-67 labeling index (Ki-67 LI) and microvascular invasion (MVI) are critical prognostic biomarkers in hepatocellular carcinoma (HCC). Preoperative, noninvasive prediction of their dual positivity status remains challenging. This study aimed to develop and validate a combined model integrating radiomic features from gadoxetic acid disodium (Gd-EOB-DTPA)-enhanced magnetic resonance imaging (MRI) with clinical data. It also aimed to assess the effectiveness of combining Gd-EOB-DTPA-enhanced MRI radiomics with clinical features for the preoperative prediction of Ki-67/MVI dual positivity in HCC. A total of 142 pathologically confirmed HCC patients were categorized into dual-positive (Ki-67 LI > 20% and MVI-positive) and non-dual-positive (Ki-67 LI ≤ 20% and/or MVI-negative) groups. Clinical variables (sex, age, hepatitis status, tumor diameter, alpha-fetoprotein [AFP], liver function, inflammatory indices, and tumor differentiation), along with MRI data, were analyzed. Radiomic features were extracted from hepatobiliary-phase regions of interest. Key predictors were selected using the least absolute shrinkage and selection operator and multivariate logistic regression to construct the nomogram. The model was evaluated using the receiver operating characteristic curves, calibration plots, and decision curve analysis. Tumor diameter, AFP, gamma-glutamyl transferase, and differentiation grade significantly differed between the groups (P < .05), and 6 radiomic features were selected to generate a radiomics score. Multivariate analysis identified tumor diameter, AFP, and radiomics score as independent predictors of dual positivity for Ki-67/MVI. The combined model demonstrated excellent calibration and superior predictive performance, achieving an area under the curve of 0.879, sensitivity of 70.0%, specificity of 92.3%, accuracy of 78.8%, precision of 93.3%, and F1-score of 80%. Follow-up after surgery showed a significantly higher early recurrence rate in the dual-positive HCC (Ki-67/MVI) group than that in the non-dual-positive group (P < .05). The Gd-EOB-DTPA-enhanced MRI radiomics-clinical nomogram effectively predicted preoperative Ki-67/MVI dual positivity in HCC. This combined method surpassed the individual-modality models, providing significant assistance in risk assessment and tailored treatment planning for patients with HCC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.